AbbVie announced a new $380 million investment aiming to build two active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus.

API manufacturing involves producing the active components responsible for a medication’s therapeutic effects through a complex, multi-step process.¹

The company says the state-of-the-art facilities is expected to integrate advanced manufacturing technologies with artificial intelligence to support production of its next-generation neuroscience and obesity medications.¹

Construction is scheduled to begin in spring 2026, with both facilities expected to be fully operational in 2029.¹

To support the expansion, AbbVie plans to hire 300 employees in North Chicago, including engineers, scientists, manufacturing operators, and lab technicians.

“This milestone demonstrates further progress against our $100 billion commitment to U.S. R&D and capital investments over the next decade,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients.”

Over the past six months AbbVie has announced plans to significantly expand its API manufacturing capacity in the United States, a in September 2025, the company broke ground on a new chemical synthesis facility intended to return API production for select neuroscience, immunology, and oncology products from Europe and Asia to the U.S.

Bora and GSK renew five-year manufacturing partnership

In a separate announcement, Bora Pharmaceuticals Co., Ltd. and GSK signed a strategic agreement renewing a five-year manufacturing partnership.

The two companies have good relations, as Bora purchased its Mississauga facility from GSK in 2020, and the renewed collaboration expands the relationship by giving GSK access to multiple Bora sites, including its oral solid dose site in Maple Grove, Minnesota.²

“Ultimately, partnerships are realized on the manufacturing floor,” said John Lawrie, VP of operations at Bora’s Mississauga site. “Our teams, systems, and processes are ready to deliver on time in full consistently to support the continued manufacture of GSK’s medicines.”

GSK stands as the largest pharmaceutical partner operating at Bora’s Mississauga facility, where Bora provides end-to-end manufacturing services for more than 20 commercial product lines and over 335 individual products.²

The medicines span indications including HIV, malaria, pneumonia, parasitic infections, depression, migraine, acne, eczema, and psoriasis.

Under the renewed agreement, GSK will continue to leverage Bora’s development teams and global commercial manufacturing infrastructure to maintain supply of these therapies.

“Strong partnerships like this are foundational to the continued growth of Bora’s CDMO business,” said J.D. Mowery, president of Bora’s CDMO division. “GSK’s continued trust in Bora reflects our strong execution across development and commercial manufacturing and supports our momentum as we expand our role as a global CDMO of choice.”

Since joining the Bora network in 2020, the Mississauga site has expanded its technical capabilities and customer base, supporting 32 clients, advancing 61 products, and completing more than 400 project and development batches.²

The company said targeted investments in flexible manufacturing technologies have reinforced its ability to deliver quality, cGMP manufacturing globally.

“From day one, this partnership was built on mutual trust and a shared commitment to quality,” shared Bobby Sheng, chairman of Bora Group and CEO of Bora. “Reaching nearly a decade of collaboration with GSK and committing through 2030 speaks to our shared focus on value and reliability. We’re grateful for the opportunity to continue supporting GSK’s mission and the patients who rely on these therapies.”

Sources

1. AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States AbbVie February 23, 2026 https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States
2. Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract Bora Pharmaceuticals February 23, 2026 https://www.businesswire.com/news/home/20260223833168/en/Bora-Pharmaceuticals-and-GSK-Sign-%24250M-Five-Year-Global-Manufacturing-Contract